2018 ICD-O-3 Updates in Table Format with Annotation for Reference
|
|
|
- Erin Elliott
- 5 years ago
- Views:
Transcription
1 Status Histology Description (this may be preferred term or a synonym) Report Comments New term Urachal carcinoma (C65.9, C66.9, C67._, C68._) New term Combined large cell neuroendocrine carcinoma (C34._, C37.9) Midline carcinoma of children and young adults with NUT rearrangement (C30.0, C31.9, C34._) NUT carcinoma (C30.0, C31.9, C34._) NUT midline carcinoma (C30.0, C31.9, C34._) New term High-grade neuroendocrine carcinoma (C54._, C55.9) New term Neuroendocrine carcinoma, poorly differentiated (C50._) New term Small cell carcinoma pulmonary type (C56.9) New term Small cell carcinoma, hypercalcemic type (C56.9) Condylomatous carcinoma (C60.0-C60.2, C60.9) 8051/3 All other sites use 8051/ forward Warty carcinoma (C60.0-C60.2, C60.9) 8051/3 All other sites use 8051/ forward /term /term Differentiated penile intraepithelial neoplasia (C60._) N Not reportable for 2018 cases Differentiated-type vulvar intraepithelial neoplasia (C51._) N Not reportable for 2018 cases Squamous cell carcinoma, HPV-positive (C01.9, C10.2, C10.3, C10.8, C10.9, C31.0 C31.3, C31.9) Squamous cell carcinoma, HPV-negative (C01.9, C10.2, C10.3, C10.8, C10.9, C31.0 C31.3, C31.9) Lipid-rich urothelial carcinoma (C65.9, C66.9, C67._, C68._) Microcystic urothelial carcinoma (C65.9, C66.9, C67._, C68._) Nested urothelial carcinoma (C65.9, C66.9, C67._, C68._) Squamotransitional cell carcinoma (C53._) Urothelial carcinoma with divergent differentiation (C65.9, C66.9, C67._, C68._) Urothelial carcinoma with squamous differentiation (C65.9, C66.9, C67._, C68._) Urothelial carcinoma with trophoblastic differentiation (C65.9, C66.9, C67._, C68._) Clear cell (glycogen-rich) urothelial carcinoma (C65.9, C66.9, C67._, C68._) New term Minimally invasive adenocarcinoma, NOS (C34._) New term Endocervical adenocarcinoma usual type (C53._) New term Acinar adenocarcinoma (C61.9 ONL) For prostate only, do not use 8550/3 New term Enteric adenocarcinoma (C34. 0, C65.9, C66.9, C67._, C68._) New term Intestinal-type adenocarcinoma (C30.0, C53._) New term Mucinous carcinoma, intestinal type (C53._)
2 Status Histology Description (this may be preferred term or a synonym) Report Comments ACTH-producing tumor N Endocrine tumor, functioning, NOS N Adenocarcinoma, pancreatobiliary-type (C24.1) 8255/ Pancreatobiliary-type carcinoma (C24.1) 8255/3 New term Thymic carcinoma with adenoid cystic carcinoma-like features (C37.9) /term Serrated adenocarcinoma (C18.0, C18.2, C18.9, C19.9, C20.9) New term Neuroendocrine tumor, well differentiated (C50._) /term Adenocarcinoma in situ, non-mucinous (C34._) New term Lepidic adenocarcinoma (C34._) New term Lepidic predominant adenocarcinoma (C34._) /term Adenocarcinoma in situ, mucinous (C34._) Important note: lung primaries ONL: For cases diagnosed 1/1/2018 forward do not use 8480 (mucinous adenocarcinoma) for in-situ adenocarcinoma, mucinous or invasive mucinous adenocarcinoma. New term Invasive mucinous adenocarcinoma (C34._) Important note: lung primaries ONL: For cases diagnosed 1/1/2018 forward do not use 8480 (mucinous adenocarcinoma) for in-situ adenocarcinoma, mucinous or invasive mucinous adenocarcinoma. New term Mixed invasive mucinous and non-mucinous adenocarcinoma (C34._) Minimally invasive adenocarcinoma, non-mucinous (C34._) Minimally invasive adenocarcinoma, mucinous (C34._) New term Endometrioid adenocarcinoma, villoglandular (C54._, C55.9) New term Villoglandular carcinoma (C53._) Micropapillary carcinoma, NOS (C18._, C19.9, C20.9, C34._) 8507/3. Code 8265 is not valid for C50._. Use 8507 for micropapillary adenocarcinoma in breast primaries Micropapillary adenocarcinoma (C34._) 8507/3. Code 8265 is not valid for C50._. Use 8507 for micropapillary adenocarcinoma in breast primaries /term /term Hereditary leiomyomatosis & RCC- associated renal cell carcinoma (C64.9) MiT family translocation renal cell carcinoma (C64.9)
3 Status Histology Description (this may be preferred term or a synonym) Report Comments New term Renal cell carcinoma, unclassified (C64.9) New term Acquired cystic disease-associated renal cell carcinoma (RCC) (C64.9) New term Tubulocystic renal cell carcinoma (C64.9) Follicular thyroid carcinoma (FTC), encapsulated angoinvasive (C73.9) New term Non-invasive EFVPTC (C73.9) New term Non-invasive encapsulated follicular variant of papillary thyroid carcinoma (non-invasive EFVPTC) (C73.9) New term Non-invasive follicular thyroid neoplasm with papillary-like nuclear features (NIFTP) (C73.9) New term Non-invasive FTP (C73.9) New term Encapsulated follicular variant of papillary thyroid carcinoma, NOS (EFVPTC, NOS) (C73.9) New term Invasive encapsulated follicular variant of papillary thyroid carcinoma (invasive EFVPTC) (C73.9) /term Atypical hyperplasia/endometrioid intraepithelial neoplasm (C54._) N Not reportable for 2018 cases /term /term Serous endometrial intraepithelial carcinoma (C54._, C55.9) Serous tubal intraepithelial carcinoma (C57.0) New term Intraductal papillary mucinous neoplasm with high-grade dysplasia (C25._) New term /term /term New term Intraductal papillary mucinous neoplasm (IPMN) with an associated invasive carcinoma (C25._) Non-invasive low grade serous carcinoma (C56.9) Serous borderline tumor-micropapillary variant (C56.9) N Not reportable for 2018 cases Low-grade serous carcinoma (C56.9, C48._, C57.0, C57.1 C57.3) New term High-grade serous carcinoma (C48._, C56.9, C57.0, C57.1 C57.3) New term Mucinous cystic tumor with associated invasive carcinoma (C25._) Seromucinous carcinoma (C56.9) Low grade appendiceal mucinous neoplasm (C18.1) N New term Mucinous tubular and spindle cell carcinoma (C64.9) New term Mucinous carcinoma, gastric type (C53._) New term Low grade cribriform cystadenocarcinoma (LGCCC) (C06.9, C08.9) New term Mammary carcinoma, in situ (C50._) New term Non-invasive mammary carcinoma (C50._) New term Salivary duct carcinoma (C06.9, C08.9) New term Invasive carcinoma of no special type (C50._) New term Invasive carcinoma, NST (C50._)
4 Status Histology Description (this may be preferred term or a synonym) Report Comments New term Invasive mammary carcinoma (C50._) New term Intraductal papilloma with ductal carcinoma in situ (C50._) New term Intraductal tubulopapillary neoplasm (C25._) New term Intracystic papillary neoplasm with associated invasive carcinoma New term Encapsulated papillary carcinoma C50._) New term Encapsulated papillary carcinoma with invasion (C50._) /term Invasive micropapillary carcinoma (C50._) Solid papillary carcinoma in situ (C50._) Solid papillary carcinoma with invasion (C50._) New term Renal medullary carcinoma (C64.9) For all sites other than C50._, see 8265/ Pleomorphic lobular carcinoma in situ (C50._) ICD-O-3 rule F DOES NOT APPL to Invasive pleomorphic lobular carcinoma is d 8520/3 New term Intraductal papilloma with lobular carcinoma in situ (C50._) New term Invasive lobular carcinoma, alveolar type (C50._) New term Invasive lobular carcinoma, solid type (C50._) New term Invasive lobular carcinoma, tubulolobular variant (C50._) New term Pleomorphic lobular carcinoma (C50._) New term Invasive lobular carcinoma (C50._) New term Tubulolobular carcinoma (C50._) New term Acinar cell carcinoma Excludes C61.9-see 8140/3 New term Acinar adenocarcinoma (C34._) Lung primaries diagnosed prior to 1/1/2018 use 8550/3; for prostate (all years) see 8140/ Mixed acinar ductal carcinoma 8523/3 New term Endometrioid carcinoma with squamous differentiation (C54._, C55.9) New term Low grade adenosquamous carcinoma (C50._) New term Carcinoma with chondroid differentiation (C50._) New term Carcinoma with osseous differentiation (C50._) New term Metaplastic carcinoma with chondroid differentiation (C50._) New term Metaplastic carcinoma with osseous differentiation (C50._) New term Acinar adenocarcinoma, sarcomatoid (C61.9) New term Fibromatosis-like metaplastic carcinoma (C50._) New term New term Adenocarcinoma admixed with neuroendocrine carcinoma (C53._) Carcinoma with other types mesenchymal differentiation (C50._)
5 Status Histology Description (this may be preferred term or a synonym) Report Comments New term Metaplastic carcinoma with other types mesenchymal differentiation (C50._) New term Metaplastic carcinoma of no special type (C50._) /term Mixed germ cell sex cord-stromal tumor, unclassified (C48.2, C56.9, C57.9) Adult granulosa cell tumor (C56.9 ONL) N Not reportable for 2018 cases Malignant perivascular epithelial cell tumor PEComa, malignant Perivascular epithelioid cell tumor, malignant New term Meningeal melanoma (C70._, C71._) New term Undifferentiated spindle cell sarcoma New term Undifferentiated pleomorphic sarcoma New term Undifferentiated round cell sarcoma New term Undifferentiated epithelioid sarcoma New term Undifferentiated uterine sarcoma /term New term Myxoinflammatory fibroblastic sarcoma (MIFS) (C49._) N Solitary fibrous tumor/hemangiopericytoma Grade 1 (CNS) N Reportable for CNS New term/behavior Solitary fibrous tumor/hemangiopericytoma Grade 2 (CNS) Reportable for CNS ONL New term Solitary fibrous tumor/hemangiopericytoma Grade 3 (CNS) /term /term Low-grade myofibroblastic sarcoma ( C01.9, C02._, C06.9, C49._) Myofibroblastic sarcoma New term Malignant fibrous histiocytoma (MFH) of bone New term Undifferentiated high-grade pleomorphic sarcoma New term Fibrosarcomatous dermatofibrosarcoma protuberans New term Low-grade fibromyxoid sarcoma New term Sclerosing epithelioid fibrosarcoma /term /term Ossifying fibromyxoid tumor, malignant (C49._) Pulmonary myxoid sarcoma with EWSR1-CREB1 translocation (C34._) New term Sclerosing rhabdomyosarcoma New term Mullerian adenosarcoma (C54._, C55.9) /term Calcifying nested epithelial stromal tumor (C22.0) N Adenomyoepithelioma with carcinoma (C50._) New term Phosphaturic mesenchymal tumor, malignant New term Periductal stromal tumor, low grade (C50._) Biphenotypic sinonasal sarcoma (C30.0, C31.0-C31.3, C31.8, C31.9) Germ cell tumors with associated hematological malignancy (C37.9)
6 Status Histology Description (this may be preferred term or a synonym) Report Comments New term Adenocarcinoma of rete ovarii (C56.9) /term Epithelioid hemangioendothelioma Intimal sarcoma Pulmonary artery intimal sarcoma New term Low-grade central osteosarcoma (C40._, C41._) New term Low-grade intramedullary osteosarcoma (C40._, C41._) New term Chondrosarcoma grade 2/3 /term /term Ghost cell odontogenic carcinoma (C41.0, C41.1) Clear cell odontogenic carcinoma (C41.0, C41.1) New term Anaplastic oligoastrocytoma New term Oligoastrocytoma, NOS Diffuse midline glioma, H3 K27M-mutant Papillary tumor of pineal region (C75.3) Ependymoma, RELA fusion-positive New term Diffuse astrocytoma, IDH-mutant New term Diffuse astrocytoma, IDH-wildtype New term Anaplastic astrocytoma, IDH-mutant New term Anaplastic astrocytoma, IDH-wildtype New term Anaplastic pleomorphic xanthroastrocytoma 9361/ Pilomyxoid astrocytoma Angiocentric glioma Pituicytoma (C75.1) 9421/3 9380/1 9380/1 New term Epithelioid glioblastoma New term Glioblastoma, IDH wildtype New term Glioblastoma, IDH-mutant Oligodendroglioma, IDH-mutant and 1p/19q-leted New term Anaplastic oligodendroglioma, IDH-mutant and 1p/19q leted New term Medulloblastoma, classic New term Medulloblastoma, SHH-activated and TP53-wildtype Medulloblastoma, WNT-activated Medulloblastoma, SHH-activated and TP53 mutant Medulloblastoma, group Medulloblastoma, group Medulloblastoma, non-wnt/non-shh
7 Status Histology Description (this may be preferred term or a synonym) Report Comments Embryonal tumor with multilayered rosettes C19MC-altered Embryonal tumor with multilayered rosettes, NOS New term CNS Embryonal tumor with rhabdoid features New term Embryonal tumor with rhabdoid features /term Diffuse leptomeningeal glioneuronal tumor Papillary glioneuronal tumor Rosette-forming glioneuronal tumor Epithelioid malignant peripheral nerve sheath tumor (C47.0- C47.6, C47.8, C47.9) Melanotic schwannoma (C72.4, C72.5) Indolent systemic mastocytosis N 9505/1 9505/1 9505/1
Effective January 1, 2018 ICD O 3 codes, behaviors and terms are site specific
Effective January 1, 2018 codes, behaviors and terms are site specific /N 8551/3 Acinar adenocarcinoma (C34. _) Lung primaries diagnosed prior to 1/1/2018 use code 8550/3 For prostate (all years) see 8140/3
Effective January 1, 2018 ICD O 3 codes, behaviors and terms are site specific
Effective January 1, 2018 codes, behaviors and terms are site specific Status /N 8010/3 Urachal carcinoma (C65.9, C66.9, C67. _, C68._) 8013/3 Combined large cell neuroendocrine carcinoma (C34. _, C37.9)
2 Berkeley Street, Suite 403, Toronto, Ontario M5A 2W3 Visit us at: Tel: Fax:
E-Path A.I. Engine Knowledge Base Enhancements Version 1.0.0.29 April 1, 2018 The major enhancements in the E-Path Knowledge Base from versions 1.0.0.28 through 1.0.0.29 are as follows: 1. Addition/modification
Summary NAACCR: What you need to know for 2017 Version 1.1. March ICD-O-3 Histologies. Reportability There are no reportability changes in 2017.
Summary NAACCR: What you need to know for 2017 Version 1.1. March 2017 ICD-O-3 Histologies 2.1 New Terms and Codes Not Yet Implemented ICD-O-3 s and terms effective for 2015 was postponed due to CSv2 software
S2199 S2200. * Speaker's diagnosis 78
98 21 2 14 13:30 * Speaker's diagnosis 78 S2199 Meningioma 48 Papillary meningioma * 30 Angiomatous meningioma 15 Ependymoma 12 Papillary ependymoma 6 Anaplastic ependymoma 2 Cellular ependymoma 1 Hemangioblastoma
2018 Updates to National Standards
2018 Updates to National Standards 1 F C D S A N N U A L C O N F E R E N C E O R L A N D O, F L O R I D A 7 / 2 6 / 2 0 1 7 S T E V E N P E A C E, C T R ICD-O-3 New Histology Codes ICD-O-3 Behavior Changes
Appendix 4: WHO Classification of Tumours of the pancreas 17
S3.01 The WHO histological tumour type must be recorded. CS3.01a The histological type of the tumour should be recorded based on the current WHO classification 17 (refer to Appendices 4-7). Appendix 4:
2018 SEER Solid Tumor Manual 2018 KCR SPRING TRAINING
2018 SEER Solid Tumor Manual 2018 KCR SPRING TRAINING Eight Groups are Revised for 2018 Head & Neck Colon (includes rectosigmoid and rectum for cases diagnosed 1/1/2018 forward) Lung (2018 Draft not yet
ICD-O Morphology code. R=Rare Tier Tumour ICD-O Topography code C30.0, C31
R=Rare Tier Tumour ICD-O Topography code ICD-O Morphology code EPITHELIAL TUMOURS OF NASAL CAVITY AND SINUSES R 2 Squamous cell carcinoma with variants of nasal cavity and sinuses C30.0, C3 C30.0, C3 8000,
Contents Part I Introduction 1 General Description 2 Natural History: Importance of Size, Site, Histopathology
Contents Part I Introduction 1 General Description... 3 1.1 Introduction... 3 1.2 Incidence and Prevalence... 5 1.3 Predisposing and Genetic Factors... 8 References... 16 2 Natural History: Importance
DATA STANDARDS AND QUALITY CONTROL MEMORANDUM DSQC #
DATA STANDARDS AND QUALITY CONTROL MEMORANDUM DSQC #2006-01 CATEGORY: CLARIFICATION SUBJECT: RESCINDMENT - DSQC MEMORANDUM 2002-08 Coding Complex Morphologic Diagnoses (revised 8/02) EFFECTIVE: For Cases
CODING TUMOUR MORPHOLOGY. Otto Visser
CODING TUMOUR MORPHOLOGY Otto Visser INTRODUCTION The morphology describes the tissue of the tumour closest to normal tissue Well differentiated tumours are closest to normal Undifferentiated tumours show
Rare Breast Tumours. 1. Breast Tumours. 1.1 General Results. 1.2 Incidence
Rare Breast Tumours 1. Breast Tumours 1.1 General Results Table 1. Epithelial Tumours of Breast: Incidence, Trends, Survival Flemish Region 2001-2010 Incidence Trend Survival Females EAPC Relative survival
incidence rate x 100,000/year
Tier R=rare C=common Cancer Entity European crude and age adjusted incidence by cancer, years of diagnosis 2000 and 2007 Analisys based on 83 population-based cancer registries * applying the European
Annual report of the Committee on Gynecologic Oncology, the Japan Society of Obstetrics and Gynecology
bs_bs_banner doi:10.1111/jog.12596 J. Obstet. Gynaecol. Res. Vol. 41, No. 2: 167 177, February 2015 Annual report of the Committee on Gynecologic Oncology, the Japan Society of Obstetrics and Gynecology
FINALIZED SEER SINQ QUESTIONS
0076 Source 1: WHO Class CNS Tumors pgs: 33 MP/H Rules/Histology--Brain and CNS: What is the histology code for a tumor originating in the cerebellum and extending into the fourth ventricle described as
4/12/2018. MUSC Pathology Symposium Kiawah Island April 18, Jesse K. McKenney, MD
MUSC Pathology Symposium Kiawah Island April 18, 2018 Jesse K. McKenney, MD 1 Urothelial Carcinoma with Alternative Differentiation 2 Urothelial Carcinoma with Alternative Differentiation Recognition as
GUIDELINES FOR ICD-O-3 UPDATE IMPLEMENTATION Effective January 1, 2014
North American Association of Central Cancer Registries, Inc. GUIDELINES FOR ICD-O-3 UPDATE IMPLEMENTATION Effective January 1, 2014 Prepared by the NAACCR ICD-O-3 Update Implementation Work Group December
Gross appearance of nodular hyperplasia in material obtained from suprapubic prostatectomy. Note the multinodular appearance and the admixture of
Tiền liệt tuyến Tiền liệt tuyến Gross appearance of nodular hyperplasia in material obtained from suprapubic prostatectomy. Note the multinodular appearance and the admixture of solid and microcystic areas.
Lung Tumor Cases: Common Problems and Helpful Hints
Lung Tumor Cases: Common Problems and Helpful Hints Brandon T. Larsen, MD, PhD Senior Associate Consultant Department of Laboratory Medicine and Pathology Mayo Clinic Arizona Arizona Society of Pathologists
* Speaker's diagnosis
* Speaker's diagnosis Creutzfeldt-Jacob disease(cjd) 5 Prion disease( Creutzfeldt-Jakob disease ) 3 Extrapontine myelinolytis 5 Subacute sclerosing panencephalitis (SSPE) 5 Central pontine myelinolysis
Supplementary Information
Rise in Glioblastoma Multiforme incidence in England 1995 2015 suggests an adverse environmental or lifestyle factor Alasdair Philips, Denis L Henshaw, Graham Lamburn, Michael J O Carroll Supplementary
Vulva Inflammatory Disorders Lichen Planus Fixed Drug Eruption Erythema Multiforme Plasmacytosis Mucosae (Zoon) Lichen Sclerosus Allergic Contact
Vulva Inflammatory Disorders Lichen Planus Fixed Drug Eruption Erythema Multiforme Plasmacytosis Mucosae (Zoon) Lichen Sclerosus Allergic Contact Dermatitis Psoriasis Lichen Simplex Chronicus Foreign Body
S Y M P O S I U M P R O G R A M
Dear colleagues, dear friends We would like to cordially welcome you to the 10 th International Arkadi M. Rywlin International Pathology Slide Seminar in Anatomic Pathology to be held in Split, Croatia.
Differential Diagnosis of Oral Masses. Palatal Lesions
Differential Diagnosis of Oral Masses Palatal Lesions Palatal Masses Periapical Abscess Torus Palatinus Mucocele Lymphoid Hyperplasia Adenomatous Hyperplasia Benign Salivary Neoplasms Malignant Salivary
BMaP-3 Cancer Database. Aggregate Data File
BMaP-3 Cancer Database Aggregate Data File Contents BMaP-3 Cancer Database... 1 Aggregate Data File... 1 Frequency Tables... 2 Institution... 2 Year_First_Contact... 2 Primary_Site... 3 Sex... 3 Race...
Methoden / Methods inc. ICCC-3 105
Methoden / Methods inc. ICCC-3 105 Internationale Klassifikation der Krebserkrankungen bei Kindern (ICCC-3) Zuordnung von ICD-O-3-Codes für Morphologie und Topographie zu diagnostischen Kategorien International
Protocol for the Examination of Biopsy Specimens From Patients With Invasive Carcinoma of the Breast
Protocol for the Examination of Specimens From Patients With Invasive Carcinoma of the Breast Version: BreastInvasive 1.0.0.0 Protocol Posting Date: February 2019 Accreditation Requirements The use of
Donna M. Hansen, CTR Auditor & Training Coordinator California Cancer Registry
Donna M. Hansen, CTR Auditor & Training Coordinator California Cancer Registry April 2015 2015 Data Changes New Data Items Revised Data Items ICD-0-3 Reportability Change New ICDO Terms and Codes SEER
Minimally invasive adenocarcinoma. 5mm or less = microinvasion No necrosis No lymphatic or pleural invasion No spread through air-spaces (STAS)
Minimally invasive adenocarcinoma 5mm or less = microinvasion No necrosis No lymphatic or pleural invasion No spread through air-spaces (STAS) 2b lepidic acinar 2c papillary micropapillary solid 2d cribriform
Normal endometrium: A, proliferative. B, secretory.
Normal endometrium: A, proliferative. B, secretory. Nội mạc tử cung Nội mạc tử cung Cyclic changes in endometrium.. Approximate relationship of useful microscopic changes. Arias-Stella reaction in endometrial
Surveys and Anatomic Pathology Education Programs
Surveys and Anatomic Pathology Education Programs Performance Improvement Program in Surgical Pathology PIP/PIPW-B 2017 Participant Summary 2017 College of American Pathologists. The College does not permit
North American Association of Central Cancer Registries, Inc. (NAACCR) What You Need to Know for Version 1.1
North American Association of Central Cancer Registries, Inc. (NAACCR) What You Need to Know for 2017 Version 1.1 January 2017 Revised March 2017 Table of Contents 1 Introduction... 3 2 ICD-O-3 Histologies...
Pathology Mystery and Surprise
Pathology Mystery and Surprise Tim Smith, MD Director Anatomic Pathology Medical University of South Carolina Disclosures No conflicts to declare Some problem cases Kidney tumor Scalp tumor Bladder tumor
2007 Multiple Primary and
2007 Multiple Primary and Histology Coding Rules Beyond the Basics Florida Cancer Data System Annual Conference Tampa, FL July 26,2007 Steven Peace, CTR Westat Carol Johnson, CTR NCI SEER Peggy Adamo,
List of Available TMAs in the PRN
TMA RPCI_BrainCa01 RPCI_BrCa03 RPCI_BrCa04 RPCI_BrCa05 RPCI_BrCa0 RPCI_BrCa07 RPCI_BrCa08 RPCI_BrCa15 RPCI_BrCa1 RPCI_BrCa17 RPCI_BrCa18 RPCI_BrCa19 RPCI_BrCa20 RPCI_BrCa21 RPCI_BrCa24 RPCI_BrCa25 RPCI_BrCa2
Disclosures. An update on ancillary techniques in the diagnosis of soft tissue tumors. Ancillary techniques. Introduction
Disclosures An update on ancillary techniques in the diagnosis of soft tissue tumors. I have nothing to disclose. Andrew Horvai, MD, PhD Clinical Professor, Pathology Introduction Ancillary techniques
Disclosures. An update on ancillary techniques in the diagnosis of soft tissue tumors. Ancillary techniques. Introduction
Disclosures An update on ancillary techniques in the diagnosis of soft tissue tumors. I have nothing to disclose. Andrew Horvai, MD, PhD Clinical Professor, Pathology Introduction Ancillary techniques
What is New in the 2015 WHO Lung Cancer Classification? Zhaolin Xu, MD, FRCPC, FCAP
What is New in the 2015 WHO Lung Cancer Classification? Zhaolin Xu, MD, FRCPC, FCAP Professor, Dept of Pathology, Dalhousie University, Canada Pulmonary Pathologist and Cytopathologist, QEII HSC Senior
Other Sites. Table 2 Continued. MPH Rules 11/8/07. NAACCR Webinar Series 1
MPH s 11/8/07 Other s 1 Table 2 Continued Use this two-page table to select combination histology codes. Compare the terms in the diagnosis to the terms in Columns 1 and 2. If the terms match, code the
SUPPLEMENTARY INFORMATION
Supplementary Table 1 trials currently open for patients with pheochromocytoma and/or paraganglima (from trials.gov) www.clinicaltrials.gov; Active PPGL trials Status Of Sunitinib In Patients With Recurrent
Neoplasias Quisticas del Páncreas
SEAP -Aproximación Práctica a la Patología Gastrointestinal- Madrid, 26 de mayo, 2006 Neoplasias Quisticas del Páncreas Gregory Y. Lauwers, M.D. Director, Service Massachusetts General Hospital Harvard
Spindle Cell Lesions Of The Breast. Emad Rakha Professor of Breast Pathology and Consultant Pathologist
Spindle Cell Lesions Of The Breast Emad Rakha Professor of Breast Pathology and Consultant Pathologist * SCLs comprise a wide spectrum of diseases, ranging from reactive processes to aggressive malignant
CURRICULUM FOR THE BREAST PATHOLOGY ROTATION UNIVERSITY OF FLORIDA DEPARTMENT OF PATHOLOGY
CURRICULUM FOR THE BREAST PATHOLOGY ROTATION UNIVERSITY OF FLORIDA DEPARTMENT OF PATHOLOGY JULY, 2003 The following is a conceptual curriculum and set of guidelines for Pathology Residents on the Breast
The European Commission s science and knowledge service. Joint Research Centre
The European Commission s science and knowledge service Joint Research Centre Coding Primary Site and Tumour Morphology JRC-ENCR training course Copenhagen, 25 September 2018 Nadya Dimitrova Outline What
Appendix E SEER Program Coding and Staging Manual DRAFT Reportable Examples
Appendix E1 2018 SEER Program Coding and Staging Manual DRAFT Reportable Examples Malignant # Diagnosis/Condition Notes 1 Atypical fibroxanthoma (superficial malignant fibrous histiocytoma) 2 Positive
Surveys and Anatomic Pathology Education Programs
Surveys and Anatomic Pathology Education Programs Performance Improvement Program in Surgical Pathology PIP/PIPW-B 2018 Participant Summary 2018 College of American Pathologists. The College does not permit
04/09/2018. Salivary Gland Pathology in the Molecular Era Old Friends, Old Foes, & New Acquaintances
Salivary Gland Pathology in the Molecular Era Old Friends, Old Foes, & New Acquaintances Jennifer L. Hunt, MD, MEd Aubrey J. Hough Jr, MD, Endowed Professor of Pathology Chair of Pathology and Laboratory
Salivary Glands 3/7/2017
Salivary Glands 3/7/2017 Goals and objectives Focus on the entities unique to H&N Common board type facts Information for your future practice Salivary Glands Salivary Glands Major gland. Paratid. Submandibular.
CANCER REGISTRY 2002
2 National Cancer Institute Department of Medical Services Ministry of Public Health Thailand Edited by Pattarawin Attasara, M.D. ISSN 974-7980-57-6 NATIONAL INSTITUTE STAFFS Consultant : Editor : Office
FINALIZED SEER SINQ QUESTIONS
0066 Source 1: 2016 SEER Manual pgs: 78 Notes: Primary Site Primary Site/Corpus uteri: Is the primary site C541 (endometrium) or C543 (uterine fundus) when the histology states endometrial adenocarcinoma,
VULVAR CARCINOMA. Page 1 of 5
VULVAR CARCINOMA EXAMPLE OF A VULVAR CARCINOMA USING PROPOSED TEMPLATE Case: Invasive squamous cell carcinoma arising in D-VIN Tumor in left labia major Left partial vaginectomy and sentinel lymph node
SHN-1 Human Digestive Panel Test results
SHN-1 Human Digestive Panel Test results HN-30 tongue HN-24 salivary gland HN-12 larynx HN-28 esophagus HN-29 stomach HN-20 pancreas HN-13 liver HN-14 gall bladder HN-27-1 duodenum HN-27-2 ileum HN-27-3
Papillary Lesions of the breast
Papillary Lesions of the breast Emad Rakha Professor of Breast Pathology The University of Nottingham Papillary lesions of the breast are a heterogeneous group of disease, which are characterised by neoplastic
SUPPLEMENTARY INFORMATION
VOLUME: 1 ARTICLE NUMBER: 0027 In the format provided by the authors and unedited. Rapid intraoperative histology of unprocessed surgical specimens via fibre-laser-based stimulated Raman scattering microscopy
Breast - ductal carcinoma CK7 ER PR GATA3 Mammaglobin (50-70%) GCDFP-15 (50-70%) E-cadherin HMWCK CK20 PAX2 ER/PR/HER2 on all newly diagnosed cases
Adrenal cortical carcinoma Inhibin Synap Melan-A Calretinin Vimentin Chromogr CK7 CK20 Breast - ductal carcinoma CK7 ER PR GATA3 Mammaglobin (50-70%) GCDFP-15 (50-70%) E-cadherin HMWCK CK20 PAX2 ER/PR/HER2
Rare cancers are those with an incidence rate 6/100,000
Rare cancers are those with an incidence rate 6/100,000 Layer Tumour Rate x 100,000 Patients 1 EPITHELIAL TUMOURS OF THE NASAL CAVITY and SINUSES 0.44 3,594 2 Squamous cell carcinoma and variants of the
57th Annual HSCP Spring Symposium 4/16/2016
An Unusual Malignant Spindle Cell Lesion to Involve the Breast Erinn Downs-Kelly, D.O. Associate Professor of Pathology University of Utah & ARUP Laboratories No disclosures Case 39 y/o female with no
FINALIZED SEER SINQ QUESTIONS
0067 MP/H Rules/Histology--Kidney: What is the correct histology for this diagnosis? See discussion. Procedure: Nephrectomy Laterality: Left Tumor type: SOLID VARIANT RENAL CELL CARCINOMA Nuclear grade:
ICD-O-3 UPDATES - PENDING
ICD-O-3 UPDATES - PENDING FCDS Annual Meeting July 26, 2013 Sunrise, Florida Steven Peace, CTR ICD-O-3 Work Group ICD-O-3 WORK GROUP Name April Fritz, CTR Lynn Ries, MS Lois Dickie, CTR Linda Mulvihill,
ICD-O-3 UPDATES - PENDING
ICD-O-3 UPDATES - PENDING FCDS Annual Meeting July 26, 2013 Sunrise, Florida Steven Peace, CTR ICD-O-3 Work Group ICD-O-3 WORK GROUP Name April Fritz, CTR Lynn Ries, MS Lois Dickie, CTR Linda Mulvihill,
Enterprise Interest None
Enterprise Interest None What are triple negative breast cancers? A synopsis of their histological patterns Ian Ellis Molecular Medical Sciences, University of Nottingham Department of Histopathology,
Carcinoma mammario: le istologie non frequenti. Valentina Guarneri Università di Padova IOV-IRCCS
Carcinoma mammario: le istologie non frequenti Valentina Guarneri Università di Padova IOV-IRCCS Histological diversity of breast adenocarcinomas Different histological types are defined according to specific
S2326. Paucicellular myxoid liposarcoma 1 Histiocytic sarcoma 1 Alveolar soft part sarcoma 1 Perivascular epithelioid cell tumor (PEComa) 1
S2325 Encephalitis 21 Encephalitis 4 Cerebritis 1 Meningoencephalitis 4 Acute disseminated encephalomyelitis 2 Acute encephalitis(virus) 1 Herpes simplex encephalitis* 2 Encephalitis, viral infection?
WHO 2017: New Classification of Head and Neck Tumours
WHO 2017: New Classification of Head and Neck Tumours Ilmo Leivo Department of Pathology University of Turku & Turku University Hospital FINLAND Suomen IAP Aulanko 18.05.2018 WHO 2017 New entities Simplification
ANNUAL CANCER REGISTRY REPORT-2015
CANCER STATISTICS Distribution of neoplasms ANNUAL CANCER REGISTRY REPORT-2015 Shahid Mahmood, Raqib Faraz, Aneel Yousaf, Hina Asif, Adna Atif, Farhana Badar Of a total of 5,924 new neoplasms diagnosed
Updates in Urologic Pathology WHO Made Those Changes?! Peyman Tavassoli Pathology Department BC Cancer Agency
Updates in Urologic Pathology WHO Made Those Changes?! Peyman Tavassoli Pathology Department BC Cancer Agency World Health Organization Available in Feb 2016 Frame work for reporting Major contributing
Diagnostically Challenging Cases in Gynecologic Pathology
Diagnostically Challenging Cases in Gynecologic Pathology Eric C. Huang, M.D., Ph.D. Department of Pathology and Laboratory Medicine University of California, Davis Medical Center Case 1 Presentation 38
Gross appearance of peritoneal cysts. They have a thin, translucent wall and contain a clear fluid.
Gross appearance of peritoneal cysts. They have a thin, translucent wall and contain a clear fluid. So-called multicystic benign mesothelioma. A, Gross appearance. So-called multicystic benign mesothelioma.
Layer Tumour Rate Patients 1 EPITHELIAL TUMOURS OF THE NASAL CAVITY and SINUSES Squamous cell carcinoma and variants of the Nasal Cavity
Layer Tumour Rate Patients 1 EPITHELIAL TUMOURS OF THE NASAL CAVITY and SINUSES 0.471 3060 2 Squamous cell carcinoma and variants of the Nasal Cavity and Sinuses 0.37 2615 3 Squamous carcinoma 0.24 1708
ANNUAL CANCER REGISTRY REPORT-2016, OF THE SHAUKAT KHANUM MEMORIAL CANCER HOSPITAL & RESEARCH CENTER, PAKISTAN
ANNUAL CANCER REGISTRY REPORT-2016, OF THE SHAUKAT KHANUM MEMORIAL CANCER HOSPITAL & RESEARCH CENTER, PAKISTAN Shahid Mahmood, Raqib Faraz, Aneel Yousaf, Ain ul Quader, Hina Asif, Adna Atif, Mehwish Waseem,
Detailed Table of Contents
Detailed 1 Immunostains: Introduction... 1 Natasha Rekhtman and Justin Bishop General Background... 1 Applications of Immunohistochemistry in Anatomic Pathology... 1 Markers of Differentiation at a Glance...
Case year female. Routine Pap smear
Case 1 57 year female Routine Pap smear Diagnosis? 1. Atypical glandular cells of unknown significance (AGUS) 2. Endocervical AIS 3. Endocervical adenocarcinoma 4. Endometrial adenocarcinoma 5. Adenocarcinoma
FINALIZED SEER SINQ S NOVEMBER 2011
: 20110133 Multiple primaries/heme & Lymphoid Neoplasms: A patient was diagnosed 7/31/08 with DLBCL (9680/3) (biopsy left supraclav. node), stage IIIB. Treated with chemo. 10/14/10 biopsy right supraclav.
FINALIZED SEER SINQ QUESTIONS January June, 2016
20160046 MP/H Rules/Multiple primaries/histology--rectum: How many primaries does this person have and what is the correct histology? See discussion. Rectal polyp excised in June, 2012, found to have adenocarcinoma
INDEX. in this web service Cambridge University Press
abscess. See also subareolar abscess acute mastitis, 44 lactational/puerperal mastitis, 55 mammary tuberculosis, 42 tuberculous, 43 adeno gastric, 198, 200 invasive, 157 lung, 197, 200 prostatic, 199 200
Annual report of Gynecologic Oncology Committee, Japan Society of Obstetrics and Gynecology, 2013
bs_bs_banner doi:10.1111/jog.12360 J. Obstet. Gynaecol. Res. Vol. 40, No. 2: 338 348, February 2014 Annual report of Gynecologic Oncology Committee, Japan Society of Obstetrics and Gynecology, 2013 Daisuke
Breast pathology. 2nd Department of Pathology Semmelweis University
Breast pathology 2nd Department of Pathology Semmelweis University Breast pathology - Summary - Benign lesions - Acute mastitis - Plasma cell mastitis / duct ectasia - Fat necrosis - Fibrocystic change/
Atypical Hyperplasia/EIN
EIN Atypical Hyperplasia/EIN Based on scientific and diagnostic advances, in 2014 the WHO moved that the precursor lesion for endometrioid carcinoma be atypical hyperplasia/ein, rather than what was previously
of 20 to 80 and subsequently declines [2].
![of 20 to 80 and subsequently declines [2].](/thumbs/80/81450506.jpg "of 20 to 80 and subsequently declines [2].")
- - According to the 2014 World Health Organization (WHO) classification and tumor morphology, primary ovarian tumors are subdivided into three categories: epithelial (60%), germ cell (30%), and sex-cord
Pancreatic Cytopathology: The Solid Neoplasms
Pancreatic Cytopathology: The Solid Neoplasms Syed Z. Ali, M.D. Professor of Pathology and Radiology Director of Cytopathology The Johns Hopkins Hospital Baltimore, Maryland Pancreatic Cytopathology: Past,
Update on Bladder Cancer: What s New in the 2016 WHO Classification of Bladder Tumors and 8 th Edition of AJCC Staging Manual
Update on Bladder Cancer: What s New in the 2016 WHO Classification of Bladder Tumors and 8 th Edition of AJCC Staging Manual Rajal B. Shah, M.D. Director, Urologic Pathology SHAHR6@ccf.org @rajalbshah
Molecular pathology in soft tissue tumors. Sylvia Höller Pathologie
Molecular pathology in soft tissue tumors Sylvia Höller Pathologie When do we perform molecular testing? Morphology and IHC are not clearly fitting with an entity some translocations are entity specific
Interventions for non-metastatic squamous cell carcinoma of the skin: a systematic review and pooled analysis of observational studies
Web appendix 2: SEARCH STRATEGIES Interventions for non-metastatic squamous cell carcinoma of the skin: a systematic review and pooled analysis of observational studies MEDLINE 1. exp epidemiologic studies/
Disclosure. Relevant Financial Relationship(s) None. Off Label Usage None MFMER slide-1
Disclosure Relevant Financial Relationship(s) None Off Label Usage None 2013 MFMER slide-1 Case Presentation A 43 year old male, with partial nephrectomy for a right kidney mass 2013 MFMER slide-2 2013
Immunohistochemistry in Bone and Soft Tissue Tumors. Sahar Rassi Zankoul, MD
Immunohistochemistry in Bone and Soft Tissue Tumors Sahar Rassi Zankoul, MD Introduction Bone tumors represent a wide variety of tumors of various origins and malignant potentials. These different tumor
ANNUAL CANCER REGISTRY REPORT-2017, OF THE SHAUKAT KHANUM MEMORIAL CANCER HOSPITAL & RESEARCH CENTER, PAKISTAN
ANNUAL CANCER REGISTRY REPORT-2017, OF THE SHAUKAT KHANUM MEMORIAL CANCER HOSPITAL & RESEARCH CENTER, PAKISTAN Shahid Mahmood, Raqib Faraz, Aneel Yousaf, Ain ul Quader, Hina Asif, Adna Atif, Lubna Nadeem,
Molecular Diagnostics of Head and Neck Tumors Justin A. Bishop, M.D. Associate Professor of Pathology The Johns Hopkins University Baltimore, Maryland
Molecular Diagnostics of Head and Neck Tumors Justin A. Bishop, M.D. Associate Professor of Pathology The Johns Hopkins University Baltimore, Maryland Two Main Topics Molecular insights in salivary gland
Select problems in cystic pancreatic lesions
Disclosure Select problems in cystic pancreatic lesions Five Prime Therapeutics shareholder Adicet Bio shareholder Bristol-Meyer Squibb advisory board grace.kim@ucsf.edu Pancreatic cystic lesions Intraductal
From Morphology to Molecular Pathology: A Practical Approach for Cytopathologists Part 1-Cytomorphology. Songlin Zhang, MD, PhD LSUHSC-Shreveport
From Morphology to Molecular Pathology: A Practical Approach for Cytopathologists Part 1-Cytomorphology Songlin Zhang, MD, PhD LSUHSC-Shreveport I have no Conflict of Interest. FNA on Lymphoproliferative
Update in Salivary Gland Pathology. Benjamin L. Witt University of Utah/ARUP Laboratories February 9, 2016
Update in Salivary Gland Pathology Benjamin L. Witt University of Utah/ARUP Laboratories February 9, 2016 Objectives Review the different appearances of a selection of salivary gland tumor types Establish
Financial disclosures
An update on immunohistochemical markers in mesenchymal neoplasms By Konstantinos Linos MD, FCAP, FASDP Assistant Professor of Pathology Geisel School of Medicine at Dartmouth Dartmouth-Hitchcock Medical
CANCER REGISTRY 2004
2 National Cancer Institute Department of Medical Services Ministry of Public Health Thailand Edited by Pattarawin Attasara, M.D. ISSN 974-7980-57-6 NATIONAL INSTITUTE STAFFS Consultant : Editor : Office
Recent advances in breast cancers
Recent advances in breast cancers Breast cancer is a hetrogenous disease due to distinct genetic alterations. Similar morphological subtypes show variation in clinical behaviour especially in response
Urinary Bladder: WHO Classification and AJCC Staging Update 2017
Urinary Bladder: WHO Classification and AJCC Staging Update 2017 Houston Society of Clinical Pathologists 58 th Annual Spring Symposium Houston, TX April 8, 2017 Jesse K. McKenney, MD Classification
Sentinel nodes. Location: Location: S1.04 Principal clinician. G1.01 Record other relevant information. S2.01 Number of specimens submitted
Invasive Breast Cancer Histopathology Reporting Proforma Mandatory questions (i.e. protocol standards) are in bold (e.g. S1.01). S1.01 Identification Family name Given name(s) Date of birth DD MM YYYY
Carcinoma of unknown primary origin (CUP) is defined
REVIEW ARTICLE Metastatic Carcinoma of Unknown Primary: Diagnostic Approach Using Immunohistochemistry James R. Conner, MD, PhD and Jason L. Hornick, MD, PhD Abstract: Carcinoma of unknown primary origin
The Panel Approach to Diagnostics. Lauren Hopson International Product Specialist Cell Marque Corporation
The Panel Approach to Diagnostics Lauren Hopson International Product Specialist Cell Marque Corporation Cell Marque Rocklin, California About Cell Marque: IVD primary antibody manufacturer Distributors
The role of immunohistochemistry in surgical pathology of the uterine corpus and cervix
The role of immunohistochemistry in surgical pathology of the uterine corpus and cervix Prof. Ben Davidson, MD PhD Department of Pathology, Norwegian Radium Hospital, Oslo University Hospital, Oslo, Norway
Lesion Imaging Characteristics Mass, Favoring Benign Circumscribed Margins Intramammary Lymph Node
Lesion Imaging Characteristics Mass, Favoring Benign Circumscribed Margins Intramammary Lymph Node Oil Cyst Mass, Intermediate Concern Microlobulated Margins Obscured Margins Mass, Favoring Malignant Indistinct